Stay updated on AMG 820 and Pembrolizumab Combo in Solid Tumor Clinical Trial
Sign up to get notified when there's something new on the AMG 820 and Pembrolizumab Combo in Solid Tumor Clinical Trial page.

Latest updates to the AMG 820 and Pembrolizumab Combo in Solid Tumor Clinical Trial page
- Check7 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check36 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check50 days agoChange DetectedSite version updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check72 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2.SummaryDifference0.0%

- Check79 days agoChange DetectedRevision: v3.4.1 is now displayed, replacing the previous v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check87 days agoChange DetectedAdded a Show glossary option and updated non-critical metadata labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0), which do not alter the core study details or user actions.SummaryDifference0.2%

Stay in the know with updates to AMG 820 and Pembrolizumab Combo in Solid Tumor Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AMG 820 and Pembrolizumab Combo in Solid Tumor Clinical Trial page.